An anonymous director reports

ONCOLYTICS BIOTECH TO HOST CONFERENCE CALL TO DISCUSS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

Oncolytics Biotech Inc. will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and fiscal 2024.

Conference call and webcast

Date:  Friday, March 7, 2025

Time:  8:30 a.m. ET

North American toll-free:  888-510-2154

International:  437-900-0527

Conference ID (if needed):  48422

A webcast of the call will also be available on the investor relations page of Oncolytics's website and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialling 888-660-6345 (North America) or 289-819-1450 (international) and using replay code 48422 followed by the pound key.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized phase 2 studies in metastatic breast cancer, and phase 1 and phase 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumour phenotype -- turning "cold" tumours "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances toward registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received fast-track designation from the United States Food and Drug Administration.